GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy

◆ ◆ The Wire takeaway

You should note Japan's approval of bepirovirsen opens a new finite treatment market for chronic hepatitis B, and the FDA's priority review signals faster US access to new rectal cancer therapy. These moves accelerate competition and partnerships in infectious disease and oncology drug development.